ClinicalTrials.gg
CompletedNCT00489528Updated Oct 22, 2013

Growth Hormone in the Treatment of HIV-Associated Wasting

A Phase 3 interventional study of Somatropin; Recombinant human growth hormone (r hGH) in HIV Infections and HIV Wasting Syndrome, sponsored by EMD Serono. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-22.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare physical function and lean body mass in patients getting different doses of somatropin compared to patients not getting the drug.

02

Conditions studied

  • HIV Infections
  • HIV Wasting Syndrome

Browse trials for

Keywords

  • serostim
  • Dose-Response Relationship, Drug
  • Body Composition
03

In context

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have clearly documented infection, determined by the presence of HIV confirmed by one of the following: Western blot, immunofluorescence assay, HIV culture, polymerase chain reaction (PCR) amplification, branched DNA (bDNA) signal amplification or the presence of p24 antigen. These tests may have been performed at any time in the past, but the results must be available for review by Serono prior to entry into the study.
  2. Have evidence of AIDS wasting, with at least one of the following:

    • Documented unintentional weight loss of at least 10%, or
    • In the absence of unintentional weight loss of 10%, weight less than 90% of ideal body weight (Metropolitan Height and Weight Tables), or
    • In the absence of unintentional weight loss of 10%, \< 20 kg/m².
  3. Be at least 18 years of age.
  4. Be receiving at least 90% of estimated caloric requirement on current nutritional regimen, according to a formal nutritional analysis.
  5. Meet the following laboratory testing criteria at the week -4 visit (pre study screening):

    • , ALT, and amylase \< 3 times the .
    • Fasting triglyceride level \< 500 mg/dl (or \<5.64 mmol/l).
    • Fasting glucose \< 110 mg/dl (or \< 6.1mmol/l).
  6. Be taking an antiretroviral medication that is approved or available under a Treatment IND (in the US) or a temporary approval (outside the US).

    • The subject must have been on the antiretroviral therapy for at least 8 weeks prior to study Day 1.
    • The subject must agree not to change the antiviral regimen during the 12 weeks of study drug administration (unless medically mandated).
  7. Be capable of completing all required study activities and assessments (including all required exercise performance tests).
  8. Understand and sign an document.

Exclusion criteria

Exclusion Criteria:

  1. Any medical history of the following:

    • Pancreatitis.
    • Carpal tunnel syndrome (unless resolved by surgical release).
    • Glucose intolerance [for the purpose of this protocol defined as fasting blood glucose ≥ 110 mg/dl (6.1 mmol/l), or 2 hour/random blood glucose ≥ 140 mg/dl (7.8 mg/dl)].
    • Angina pectoris.
    • Coronary artery disease.
    • Any disorder associated with moderate to severe edema (e.g., cirrhosis, nephrosis, congestive heart failure, lymphedema).
    • Allergy or to growth hormone.
  2. Any of the following medical conditions:

    • Active AIDS-defining opportunistic infection.
    • Any active , except for localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which exceeds 2 cm in size, not on active therapy).
    • A central nervous system (CNS) mass, or CNS process associated with active neurological findings.
    • Chronic diarrhea (defined as 6 or more liquid stools per day).
    • Unstable or untreated hypertension.
  3. Patients with acute critical illnesses in intensive care units due to complications following open heart or abdominal surgery, multiple accidental trauma, or with acute respiratory failure.
  4. Either of the following aspects of the medical regimen in the 30 days prior to study entry (60 days prior to receiving study drug):

    • New systemic therapy for opportunistic infection.
    • New therapy for wasting, including parenteral or oral hyperalimentation, tube feeding, anabolic or progestational agents, or appetite stimulants.
  5. Prior radiation therapy or systemic chemotherapy.
  6. Use of within the past six months or growth hormone within the past year.
  7. An untreated or suspected serious systemic infection, or persistent fever > 101°F (or 38.5°C) during the 30 days prior to study entry.
  8. Evidence of gastrointestinal (GI) bleeding, obstruction, or malabsorption as determined by the Investigator.
  9. Active substance abuse which would prevent or compliance with study activities.
  10. Dementia which would preclude the patient from giving informed consent or complying with the requirements of this protocol.
  11. If female, be neither pregnant or breast feeding.
  12. Use of an agent under another protocol unless discussed and approved in advance by Serono's Therapeutic Director.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

What researchers measure

Primary outcomes

  1. To confirm the clinical efficacy of Serostim compared with placebo, based on an endpoint of exercise function change.

Secondary outcomes

  1. To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1997 and a completion of Mar 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2007
First posted
Jun 21, 2007
Start
Jul 1997
CompletionActual
Mar 2002
Last update
Oct 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00489528
Lead sponsor
EMD Serono
First posted
Jun 21, 2007
Start date
Jul 1997
Completion
Mar 2002
Last update
Oct 22, 2013

Study contacts

Elizabeth Svanbert, MD, PhD
study director
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion